 Berenice Gitomer
Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 32 | 2023 | 209 | 5.790 |
Why?
| | Kidney Failure, Chronic | 4 | 2020 | 489 | 1.300 |
Why?
| | Glomerular Filtration Rate | 11 | 2023 | 604 | 1.110 |
Why?
| | Kidney | 15 | 2023 | 1188 | 1.110 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 373 | 0.860 |
Why?
| | Bone Diseases | 1 | 2020 | 57 | 0.680 |
Why?
| | Hypertension | 2 | 2018 | 1056 | 0.650 |
Why?
| | Disease Progression | 15 | 2023 | 2380 | 0.630 |
Why?
| | TRPP Cation Channels | 8 | 2022 | 63 | 0.610 |
Why?
| | Death | 1 | 2018 | 107 | 0.570 |
Why?
| | Pravastatin | 4 | 2023 | 28 | 0.510 |
Why?
| | Vascular Stiffness | 4 | 2023 | 407 | 0.420 |
Why?
| | Polycystic Kidney Diseases | 2 | 2023 | 55 | 0.310 |
Why?
| | Blood Vessels | 2 | 2019 | 180 | 0.280 |
Why?
| | Young Adult | 10 | 2023 | 10465 | 0.270 |
Why?
| | Double-Blind Method | 4 | 2023 | 1660 | 0.250 |
Why?
| | Adult | 16 | 2023 | 30542 | 0.250 |
Why?
| | Tryptophan | 2 | 2023 | 136 | 0.240 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 811 | 0.240 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2387 | 0.230 |
Why?
| | Creatinine | 3 | 2022 | 425 | 0.230 |
Why?
| | Time Factors | 6 | 2022 | 6115 | 0.220 |
Why?
| | Organ Size | 4 | 2017 | 434 | 0.220 |
Why?
| | Endothelium, Vascular | 2 | 2021 | 847 | 0.210 |
Why?
| | Child | 9 | 2023 | 18407 | 0.200 |
Why?
| | Humans | 30 | 2023 | 114654 | 0.190 |
Why?
| | Curcumin | 1 | 2021 | 28 | 0.190 |
Why?
| | Metabolome | 2 | 2022 | 282 | 0.190 |
Why?
| | Minerals | 1 | 2020 | 37 | 0.180 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 35 | 0.180 |
Why?
| | Dementia | 1 | 2023 | 187 | 0.180 |
Why?
| | Overweight | 2 | 2021 | 471 | 0.170 |
Why?
| | Uric Acid | 1 | 2021 | 148 | 0.170 |
Why?
| | Metabolomics | 2 | 2022 | 521 | 0.170 |
Why?
| | Mutation | 5 | 2022 | 3345 | 0.170 |
Why?
| | Male | 19 | 2022 | 55579 | 0.160 |
Why?
| | Spironolactone | 1 | 2019 | 28 | 0.160 |
Why?
| | Vascular Diseases | 1 | 2021 | 230 | 0.160 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 38 | 0.160 |
Why?
| | Genotype | 3 | 2020 | 1760 | 0.150 |
Why?
| | Female | 18 | 2022 | 59488 | 0.150 |
Why?
| | Metformin | 1 | 2021 | 276 | 0.150 |
Why?
| | Fathers | 1 | 2018 | 45 | 0.150 |
Why?
| | Biomarkers | 4 | 2021 | 3408 | 0.150 |
Why?
| | Adolescent | 8 | 2021 | 17837 | 0.150 |
Why?
| | Adaptive Immunity | 1 | 2018 | 155 | 0.140 |
Why?
| | Obesity | 2 | 2021 | 2508 | 0.140 |
Why?
| | Energy Metabolism | 1 | 2022 | 731 | 0.140 |
Why?
| | Fibroblast Growth Factors | 1 | 2017 | 162 | 0.130 |
Why?
| | Mice | 6 | 2023 | 14863 | 0.130 |
Why?
| | Oxidative Stress | 2 | 2018 | 1076 | 0.120 |
Why?
| | Prenatal Diagnosis | 1 | 2016 | 167 | 0.120 |
Why?
| | Age of Onset | 1 | 2016 | 446 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2537 | 0.110 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 5 | 0.110 |
Why?
| | Survival Rate | 1 | 2018 | 1644 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2021 | 3003 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 687 | 0.110 |
Why?
| | Lovastatin | 1 | 2013 | 26 | 0.110 |
Why?
| | Sex Factors | 1 | 2018 | 1715 | 0.100 |
Why?
| | Middle Aged | 8 | 2021 | 26732 | 0.100 |
Why?
| | Disease Models, Animal | 3 | 2022 | 3531 | 0.100 |
Why?
| | Mothers | 1 | 2018 | 651 | 0.100 |
Why?
| | Kynurenine | 2 | 2023 | 81 | 0.100 |
Why?
| | Prospective Studies | 5 | 2021 | 6217 | 0.100 |
Why?
| | Animals | 7 | 2023 | 31698 | 0.100 |
Why?
| | Retrospective Studies | 2 | 2018 | 12544 | 0.090 |
Why?
| | Databases, Factual | 1 | 2015 | 1125 | 0.090 |
Why?
| | Mice, Inbred C57BL | 4 | 2023 | 4692 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2014 | 712 | 0.080 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 4407 | 0.080 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2010 | 351 | 0.080 |
Why?
| | Receptors, Interleukin-8B | 1 | 2008 | 23 | 0.070 |
Why?
| | Cyst Fluid | 1 | 2008 | 27 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1394 | 0.070 |
Why?
| | Cysts | 1 | 2008 | 93 | 0.070 |
Why?
| | Interleukin-8 | 1 | 2008 | 237 | 0.070 |
Why?
| | Inflammation | 3 | 2022 | 2478 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2016 | 5044 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2010 | 1879 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2017 | 1727 | 0.060 |
Why?
| | Liver Diseases | 1 | 2008 | 255 | 0.060 |
Why?
| | Blood Pressure | 2 | 2023 | 1538 | 0.060 |
Why?
| | Infant | 1 | 2016 | 7959 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 53 | 0.050 |
Why?
| | Hypercapnia | 1 | 2023 | 51 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 22 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 44 | 0.050 |
Why?
| | Endocannabinoids | 1 | 2022 | 36 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 139 | 0.050 |
Why?
| | Blood Flow Velocity | 1 | 2023 | 387 | 0.050 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 271 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2023 | 2568 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2008 | 2186 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 206 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1121 | 0.040 |
Why?
| | Liver | 1 | 2008 | 1637 | 0.040 |
Why?
| | Aged | 1 | 2018 | 19068 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 411 | 0.040 |
Why?
| | Phenotype | 2 | 2022 | 2796 | 0.040 |
Why?
| | Mosaicism | 1 | 2019 | 60 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 9087 | 0.040 |
Why?
| | Cell Line | 2 | 2018 | 2635 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2021 | 740 | 0.040 |
Why?
| | Epithelial Cells | 2 | 2018 | 950 | 0.040 |
Why?
| | Pulse Wave Analysis | 1 | 2018 | 207 | 0.040 |
Why?
| | Brachial Artery | 1 | 2018 | 176 | 0.040 |
Why?
| | Femoral Artery | 1 | 2018 | 167 | 0.040 |
Why?
| | Carotid Arteries | 1 | 2018 | 180 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 4895 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 152 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 439 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 493 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 989 | 0.030 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 3 | 0.030 |
Why?
| | Linoleic Acids | 1 | 2015 | 4 | 0.030 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 40 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3044 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 768 | 0.030 |
Why?
| | Immunotherapy | 1 | 2018 | 474 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 953 | 0.030 |
Why?
| | Registries | 1 | 2022 | 1767 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1075 | 0.030 |
Why?
| | Up-Regulation | 1 | 2017 | 807 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 13 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 16 | 0.030 |
Why?
| | Risk Factors | 2 | 2017 | 8631 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2085 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1430 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 1947 | 0.030 |
Why?
| | Albuminuria | 1 | 2014 | 164 | 0.030 |
Why?
| | United States | 2 | 2022 | 12179 | 0.030 |
Why?
| | Consensus | 1 | 2015 | 537 | 0.030 |
Why?
| | Prognosis | 1 | 2020 | 3327 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1840 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1214 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2353 | 0.020 |
Why?
| | Signal Transduction | 2 | 2018 | 4512 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2968 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4622 | 0.020 |
Why?
| | Body Mass Index | 1 | 2017 | 1958 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 1796 | 0.020 |
Why?
| | Chemokines | 1 | 2010 | 216 | 0.020 |
Why?
| | Chemokine CXCL5 | 1 | 2008 | 12 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2008 | 68 | 0.020 |
Why?
| | Cell Shape | 1 | 2008 | 54 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2010 | 367 | 0.020 |
Why?
| | Cell Polarity | 1 | 2008 | 131 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2008 | 220 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2008 | 445 | 0.020 |
Why?
| | Transfection | 1 | 2008 | 866 | 0.020 |
Why?
| | Rats | 1 | 2013 | 4958 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1131 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2008 | 685 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2008 | 1313 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 2710 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 3885 | 0.010 |
Why?
|
|
Gitomer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|